Trial Profile
Phase I Study of AZD1775 (Adavosertib) With Radiation and Temozolomide in Patients With Newly Diagnosed Glioblastoma and Evaluation of Intratumoral Drug Distribution in Patients With Recurrent Glioblastoma
Status:
Active, no longer recruiting
Phase of Trial:
Phase I
Latest Information Update: 13 Mar 2024
Price :
$35
*
At a glance
- Drugs Adavosertib (Primary) ; Temozolomide
- Indications Glioblastoma
- Focus Adverse reactions
- 11 Feb 2021 Planned primary completion date changed from 29 Jan 2021 to 30 Jun 2021.
- 11 Jun 2020 Status changed from recruiting to active, no longer recruiting.
- 11 Jun 2020 Planned primary completion date changed from 28 Sep 2020 to 29 Jan 2021.